^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TMB-L + PD-L1 expression

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule, TMB | Tumor Mutational Burden
    Entrez ID:
    29126
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    2ms
    Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer. (PubMed, Cell Biosci)
    They may serve as alternative options for predicting immunotherapy efficacy in SCLC. However, there is a scarcity of studies, and the significant heterogeneity in research findings warrants attention.
    Review • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    PD-L1 expression • TMB-L + PD-L1 expression
    over1year
    Contrastive self-supervised learning of lung tumor imaging predicts immunotherapy response (ESTRO 2023)
    Baseline thoracic computed tomography (CT) scans obtained prior to initiation of combined therapy with pembrolizumab, carboplatin, and paclitaxel were retrospectively collected and analyzed. They offer a predictive performance benefit over existing methods based on PD-L1 expression and TMB. Automated high-throughput analysis of lung cancer images can aid stratified personalized precision medicine.
    Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    PD-L1 expression • TMB-L + PD-L1 expression
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel
    over2years
    Clinicopathologic characteristics of HRAS-mutant head and neck squamous cell carcinoma (HNSCC). (ASCO 2022)
    Hm was associated with poor outcomes, higher MAPK activation, PD-L1 levels, TMB and IFN scores. This points to the oncogenic and immunomodulatory role of HRAS in HNSCC. Our findings provide additional evidence for ongoing clinical trials on combinatorial immunotherapy or PI3KCA inhibitors with FTI and demonstrate unique landscape of different point mutations; further evaluation is warranted.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CD8 (cluster of differentiation 8) • FAT1 (FAT atypical cadherin 1)
    |
    PD-L1 expression • TMB-H • HRAS mutation • TMB-L + PD-L1 expression
    over2years
    Genomic characterization and translational immunotherapy of microsatellite instability-high (MSI-H) in cholangiocarcinoma. (ASCO 2022)
    MSI-H cholangiocarcinoma has distinct genomic features, and the effect of PD-1 inhibitors immunotherapy is excellent to these patients.
    Tumor Mutational Burden • Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • KMT2D (Lysine Methyltransferase 2D) • LRP1B (LDL Receptor Related Protein 1B) • RNF43 (Ring Finger Protein 43) • ARID1B (AT-Rich Interaction Domain 1B) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • ACVR2A (Activin A Receptor Type 2A)
    |
    PD-L1 expression • TMB-H • MSI-H/dMMR • PBRM1 mutation • RNF43 mutation • TMB-L + PD-L1 expression
    3years
    Advances in immunotherapy for neuroendocrine neoplasms (PubMed, Zhonghua Wei Chang Wai Ke Za Zhi)
    Studies have shown that the efficacy of immune monotherapy in NEN is limited, and it can be considered for selected patients. Biomarkers for predicting efficacy of immunotherapy include PD-L1 expression, TMB-H, MSI-H/dMMR, etc. Combined regimens of anti-CTLA-4 and anti-PD-1/PD-L1 inhibitors, and immune checkpoint inhibitor combined with anti-angiogenic drugs or chemotherapy are promising in patients with NEN, and it is worthwhile to further explore of the responding populations.
    Journal • Tumor Mutational Burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    PD-L1 expression • TMB-H • MSI-H/dMMR • TMB-L + PD-L1 expression
    3years
    Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer. (PubMed, Curr Treat Options Oncol)
    Recently, the immune profiling and some immune-related genes also appear to be involved in the prognosis and response to immunotherapy in NSCLC. Further prospective studies are needed to derive definitive conclusions.
    Clinical • Review • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    PD-L1 expression • TMB-L + PD-L1 expression
    over3years
    The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy. (PubMed, Front Oncol)
    We included 137 patients with AGC and MGC who received PD-1 inhibitors (including Pembrolizumab, Nivolumab, Sintilimab, Toripalimab) in this study. Correction of anemia for GC patients as immunotherapy would be a strategy to improve the survival. More data was warranted to further influence this finding.
    Clinical • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • TMB-L + PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi)